Transcript PowerPoint File

ALBATROSS
Trial design: Patients with MI without heart failure were randomized to an IV bolus of
potassium canrenoate 200 mg as early as possible, then oral spironolactone 25 mg daily
for 6 months (n = 802) vs. control (n = 801).
Results
(p = 0.97)
11.8
12.2
%
• Death, resuscitated cardiac arrest, significant
ventricular arrhythmia, indication for
implantable defibrillator, or new/worsening
heart failure at 6 months: 11.8% of the
spironolactone group vs. 12.2% of the control
group (p = 0.97)
Conclusions
• Among patients with MI without heart failure,
an early aldosterone antagonist (IV potassium
canrenoate/oral spironolactone) was not
beneficial at reducing adverse cardiac events
compared with control
Spironolactone
Control
Presented by Dr. Gilles Montalescot at ESC 2015